REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 27th, 2023 • Biodexa Pharmaceuticals PLC • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of November [•], 2023, between Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
LICENSE AGREEMENT by and between BIODEXA PHARMACEUTICALS PLC and MELIOR PHARMACEUTICALS I, INC. Dated as of November 22, 2023License Agreement • November 27th, 2023 • Biodexa Pharmaceuticals PLC • Pharmaceutical preparations • New York
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
LOCK-UP AGREEMENTLock-Up Agreement • November 27th, 2023 • Biodexa Pharmaceuticals PLC • Pharmaceutical preparations • New York
This lock-up agreement (this “Agreement”) is dated as of [•], 2023, by and between Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (“Biodexa”), and the undersigned stockholder (the “Holder”). Each of Biodexa and the Holder may be referred to herein as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined in this Agreement shall have the respective meanings ascribed to such terms in the License Agreement (as defined below).
ASSIGNMENT AND EXCHANGE AGREEMENTAssignment and Exchange Agreement • November 27th, 2023 • Biodexa Pharmaceuticals PLC • Pharmaceutical preparations • New York
This ASSIGNMENT AND EXCHANGE AGREEMENT (this “Agreement”), dated as of November 22, 2023, is entered into by and among Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (“Buyer”), and Adhera Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of secured notes issued by the Company set forth on Schedule 1 hereto (the “Secured Noteholders”). The Company, Buyer and the Secured Noteholders are sometimes referred to herein collectively as the “Parties” and each individually as a “Party.” Capitalized terms used herein but not otherwise defined shall have the meaning set forth in Article I.
LOCK-UP AGREEMENTLock-Up Agreement • November 27th, 2023 • Biodexa Pharmaceuticals PLC • Pharmaceutical preparations • New York
This lock-up agreement (this “Agreement”) is dated as of [•], 2023, by and between Biodexa Pharmaceuticals, PLC, a public limited company organized under the laws of England and Wales (“Biodexa”), and the undersigned stockholder (the “Holder”). Each of Biodexa and the Holder may be referred to herein as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined in this Agreement shall have the respective meanings ascribed to such terms in the Assignment and Exchange Agreement (as defined below).
